<code id='DD5A7222D3'></code><style id='DD5A7222D3'></style>
    • <acronym id='DD5A7222D3'></acronym>
      <center id='DD5A7222D3'><center id='DD5A7222D3'><tfoot id='DD5A7222D3'></tfoot></center><abbr id='DD5A7222D3'><dir id='DD5A7222D3'><tfoot id='DD5A7222D3'></tfoot><noframes id='DD5A7222D3'>

    • <optgroup id='DD5A7222D3'><strike id='DD5A7222D3'><sup id='DD5A7222D3'></sup></strike><code id='DD5A7222D3'></code></optgroup>
        1. <b id='DD5A7222D3'><label id='DD5A7222D3'><select id='DD5A7222D3'><dt id='DD5A7222D3'><span id='DD5A7222D3'></span></dt></select></label></b><u id='DD5A7222D3'></u>
          <i id='DD5A7222D3'><strike id='DD5A7222D3'><tt id='DD5A7222D3'><pre id='DD5A7222D3'></pre></tt></strike></i>

          focus

          focus

          author:comprehensive    Page View:22178
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Ultragenyx gene therapy for rare liver ailment succeeds in late
          Ultragenyx gene therapy for rare liver ailment succeeds in late

          JonathanWiggs/GlobeStaffUltragenyxsaidThursdayafternoonthatitsgenetherapyforarareliverailment,glycog

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

          ChrisBoshoff,farright,speakingatapanelwith,fromleft,MatthewHerperofSTAT,KenKeller,LeviGarraway,andSu